In PAH, RNF213 Gene Variant a Risk Factor for Poor Outcomes, Study Says - Pulmonary Hypertension News

In PAH, RNF213 Gene Variant a Risk Factor for Poor Outcomes, Study Says - Pulmonary Hypertension News

In PAH, RNF213 Gene Variant a Risk Factor for Poor Outcomes, Study Says - Pulmonary Hypertension News

Posted: 30 Sep 2019 06:00 AM PDT

Patients with pulmonary arterial hypertension (PAH) who carry a specific mutation in the RNF213 gene have poor clinical outcomes and worse response to combination treatments, according to a study from Japan.

The study, "Poor outcomes in carriers of the RNF213 variant (p.Arg4810Lys) with pulmonary arterial hypertension," was published in The Journal of Heart and Lung Transplantation.

A 2018 study found that approximately 10% of the patients with idiopathic PAH have a specific variant in the RNF213 gene — rs112735431, or p.Arg4810Lys — consisting of an amino acid substitution of arginine to lysine in the RNF213 protein. This gene alteration has already been associated with Moyamoya disease and peripheral pulmonary stenosis.

In the current study, the scientists set out to characterize and assess the outcomes of PAH patients with this variant.

A total of 139 patients with idiopathic or possibly heritable PAH were included, all treated between April 2005 and August 2018. Patients with mutations in the BMPR2 gene — with a well-known link to PAH — were included as controls.

At both diagnosis and after combination treatment with prostaglandin I2 (PGI2) infusion, endothelin receptor antagonists (ERAs), and/or phosphodiesterase-5 inhibitors (PDE5i), the patients underwent assessments of their serum levels of B-type natriuretic peptide (BNP) — a marker of heart failure and other cardiac problems — World Health Organization (WHO) class, and six-minute walk distance (6MWD), a test of exercise capacity.

Whole-exome sequencing, which screens the DNA bits containing information to generate a protein, found the p.Arg4810Lys variant in 11 patients (7.9% of the patients, eight women), all in only one of the gene copies (heterozygous). No patient showed cerebral involvement suggestive of Moyamoya disease.

All 11 patients had clinically severe disease at diagnosis, as indicated by their BNP levels, cardiac output, mean pulmonary arterial pressure (mPAP), and pulmonary vascular resistance (PVR). Eight were treated with PGI2.

Over a mean follow-up period of 30 months, both mPAP and PVR improved with combination treatment. In contrast, BNP levels, cardiac output, WHO class, and 6MWD scores did not change.

Two of these patients had both the studied variant in RNF213 and BMPR2 gene mutations, and did not respond favorably to treatment.

Compared with the 36 patients with BMPR2 gene mutations, the nine patients with the p.Arg4810Lys variant showed significantly inferior benefits with combination therapy, including in mPAP, cardiac output, BNP levels, and 6MWD scores. These patients also showed higher diastolic pressure gradients, suggesting worse response to treatment.

Four patients died, three of whom were in the group with the RNF213 gene variant. One patient in this group and two in the group with BMPR2 mutations underwent lung transplants. The RNF213 gene variant carrier who underwent this procedure experienced clinical improvements and did not require hospital admission for five years.

Event-free rates (no death or lung transplant) since diagnosis and the start of PGI2 treatment were significantly better in patients with BMPR2 mutations. Specifically, at five years after diagnosis, all patients with BMPR2 mutation survived and did not require lung transplants, compared with 60% in the RNF213 variant group.

After introduction of PGI2, none of the patients with the RNF213 variant were event-free, compared with 93% of controls who avoided these outcomes. A similar difference favoring the group without the variant in RNF213 was also found in terms of heart failure.

Patients with RNF213 variants other than p.Arg4810Lys showed better event-free rates after diagnosis than those with these gene alterations. A subsequent analysis showed that the p.Arg4810Lys variant was a risk factor for death, lung transplant, and heart failure.

Post-mortem analysis of lung samples from two patients with the p.Arg4810Lys variant found lesions in pulmonary arteries, and marked venous wall and arterial thickness, venous occlusion, dilated capillaries, and lymph accumulation.

"Patients with idiopathic PAH who have the RNF213 p.Arg4810Lys variant are associated with severe hemodynamics, poor reactivity to vasodilator drugs, and poor clinical outcomes," the scientists wrote.

"Our findings may suggest the importance of genetic stratification of PAH to provide clinically relevant information for therapeutic strategies, leading to a personalized approach," they added.

The researchers believe that earlier consideration of a lung transplant "might be required for RNF213 p.Arg4810Lys variant carriers who are developing PAH."

  • Author Details
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer's disease.
Total Posts: 329
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer's disease.
Latest Posts

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more